Caribou Biosciences Eyes $100M NASDAQ Debut To Propel Off-The-Shelf CAR-T Therapies In Blood Cancer

  • In a filing with SEC on Thursday, Caribou Biosciences CRBU is penciling in a $100 million initial public offering.
  • The firm expects that its new shares will trade on the NASDAQ under the symbol "CRBU" once the IPO closes. 
  • BofA Securities, Citigroup, and SVB Leerink are acting as joint book-running managers for the offering.
  • The funds will give a boost to the company's three off-the-shelf CAR-T therapies, the most advanced of which is an anti-CD19 candidate (CB-010) in Phase 1 for B-cell non-Hodgkin lymphoma.
  • Some of the IPO proceeds will go to IND-enabling activities for Caribou's other two candidates, CB-011 and CB-012. 
  • The former targets BCMA to treat relapsed/refractory multiple myeloma. That candidate is expected to hit the clinic in 2022. 
  • CB-012, a CAR-T targeting CD371 for the treatment of acute myeloid leukemia. The company hopes to start human trials in 2023.
  • Though Caribou's CAR-T programs all target blood cancer, the company is working on allogeneic NK cell therapies based on induced pluripotent stem cells for solid tumors. 
  • Some of the IPO proceeds will support R&D in this area and develop the CRISPR technology it uses to make its cell therapies.
  • In March, Caribou Biosciences secured a $115 million Series C round.

Posted In: blood cancerBriefsBiotechNewsHealth CareFinancingOfferingsIPOsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.